1-3 of 3
B. Afanasyev
Close
Sort by
Journal Articles

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL).

Owen A O'Connor, J. Gerecitano, H. Van Deventer, B. Afanasyev, J. Hainsworth, M. Chen, K. Saikali, J. Seroogy, R. Escandon, A. Wolff, MG. Conlan
Journal: Blood
Blood (2009) 114 (22): 1673.
https://doi.org/10.1182/blood.V114.22.1673.1673
Published: 2009
Journal Articles

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB- 743921 Administered on Days 1 and 15 Every 28 Days without and with Prophylactic G-CSF in Non-Hodgkin or Hodgkin Lymphoma.

John Gerecitano, O. O’Connor, H. Van Deventer, J. Hainsworth, J. Leonard, A. Goy, B. Afanasyev, M. Chen, K. Saikali, M. G Conlan, R Escandon, A Wolff
Journal: Blood
Blood (2008) 112 (11): 1563.
https://doi.org/10.1182/blood.V112.11.1563.1563
Published: 2008
Journal Articles

A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin’s or Hodgkin’s Lymphoma.

Owen A. O’Connor, A. Goy, R.Z. Orlowski, J. Hainsworth, J.P. Leonard, B. Afanasyev, D. Osmanov, L.M. Reyno, M.M. Chen, R.D. Escandon
Journal: Blood
Blood (2007) 110 (11): 2556.
https://doi.org/10.1182/blood.V110.11.2556.2556
Published: 2007